Design of polyamine-based therapeutic agents: New targets and new directions

M. D Thulani Senanayake, Hemali Amunugama, Tracey D. Boncher, Robert A Casero, Patrick M. Woster

Research output: Contribution to journalArticle

Abstract

Enzymes in the biosynthetic and catabolic polyamine pathway have long been considered targets for drug development, and early drug discovery efforts in the polyamine area focused on the design and development of specific inhibitors of the biosynthetic pathway, or polyamine analogues that specifically bind DNA. More recently, it has become clear that the natural polyamines are involved in numerous known and unknown cellular processes, and disruption of polyamine functions at their effector sites can potentially produce beneficial therapeutic effects. As new targets for polyamine drug discovery continue to evolve, the rational design of polyamine analogues will result in more structurally diverse agents. In addition, the physical linkage of polyamine-like structures to putative drug molecules can have beneficial effects resulting from increases in DNA affinity and selective cellular uptake. The present chapter will summarize recent advances in the development of alkylpolyamine analogues as antitumour agents, and describe subsequent advances that have resulted from incorporating polyamine character into more diverse drug molecules. Specifically, new polyamine analogues, and the role of polyamine fragments in the design of antiparasitic agents, antitumour metal complexes, histone deacetylase inhibitors and lysine-specific demethylase 1 inhibitors, will be described.

Original languageEnglish (US)
Pages (from-to)77-94
Number of pages18
JournalEssays in Biochemistry
Volume46
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Polyamines
Therapeutics
Drug Discovery
Direction compound
Pharmaceutical Preparations
Antiparasitic Agents
Molecules
Histone Deacetylase Inhibitors
DNA
Coordination Complexes
Biosynthetic Pathways
Therapeutic Uses
Antineoplastic Agents
Lysine

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Design of polyamine-based therapeutic agents : New targets and new directions. / Senanayake, M. D Thulani; Amunugama, Hemali; Boncher, Tracey D.; Casero, Robert A; Woster, Patrick M.

In: Essays in Biochemistry, Vol. 46, No. 1, 2009, p. 77-94.

Research output: Contribution to journalArticle

Senanayake, M. D Thulani ; Amunugama, Hemali ; Boncher, Tracey D. ; Casero, Robert A ; Woster, Patrick M. / Design of polyamine-based therapeutic agents : New targets and new directions. In: Essays in Biochemistry. 2009 ; Vol. 46, No. 1. pp. 77-94.
@article{f8e1b85af99547dcb6ecb311953a4c3c,
title = "Design of polyamine-based therapeutic agents: New targets and new directions",
abstract = "Enzymes in the biosynthetic and catabolic polyamine pathway have long been considered targets for drug development, and early drug discovery efforts in the polyamine area focused on the design and development of specific inhibitors of the biosynthetic pathway, or polyamine analogues that specifically bind DNA. More recently, it has become clear that the natural polyamines are involved in numerous known and unknown cellular processes, and disruption of polyamine functions at their effector sites can potentially produce beneficial therapeutic effects. As new targets for polyamine drug discovery continue to evolve, the rational design of polyamine analogues will result in more structurally diverse agents. In addition, the physical linkage of polyamine-like structures to putative drug molecules can have beneficial effects resulting from increases in DNA affinity and selective cellular uptake. The present chapter will summarize recent advances in the development of alkylpolyamine analogues as antitumour agents, and describe subsequent advances that have resulted from incorporating polyamine character into more diverse drug molecules. Specifically, new polyamine analogues, and the role of polyamine fragments in the design of antiparasitic agents, antitumour metal complexes, histone deacetylase inhibitors and lysine-specific demethylase 1 inhibitors, will be described.",
author = "Senanayake, {M. D Thulani} and Hemali Amunugama and Boncher, {Tracey D.} and Casero, {Robert A} and Woster, {Patrick M.}",
year = "2009",
doi = "10.1042/BSE0460006",
language = "English (US)",
volume = "46",
pages = "77--94",
journal = "Essays in Biochemistry",
issn = "0071-1365",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Design of polyamine-based therapeutic agents

T2 - New targets and new directions

AU - Senanayake, M. D Thulani

AU - Amunugama, Hemali

AU - Boncher, Tracey D.

AU - Casero, Robert A

AU - Woster, Patrick M.

PY - 2009

Y1 - 2009

N2 - Enzymes in the biosynthetic and catabolic polyamine pathway have long been considered targets for drug development, and early drug discovery efforts in the polyamine area focused on the design and development of specific inhibitors of the biosynthetic pathway, or polyamine analogues that specifically bind DNA. More recently, it has become clear that the natural polyamines are involved in numerous known and unknown cellular processes, and disruption of polyamine functions at their effector sites can potentially produce beneficial therapeutic effects. As new targets for polyamine drug discovery continue to evolve, the rational design of polyamine analogues will result in more structurally diverse agents. In addition, the physical linkage of polyamine-like structures to putative drug molecules can have beneficial effects resulting from increases in DNA affinity and selective cellular uptake. The present chapter will summarize recent advances in the development of alkylpolyamine analogues as antitumour agents, and describe subsequent advances that have resulted from incorporating polyamine character into more diverse drug molecules. Specifically, new polyamine analogues, and the role of polyamine fragments in the design of antiparasitic agents, antitumour metal complexes, histone deacetylase inhibitors and lysine-specific demethylase 1 inhibitors, will be described.

AB - Enzymes in the biosynthetic and catabolic polyamine pathway have long been considered targets for drug development, and early drug discovery efforts in the polyamine area focused on the design and development of specific inhibitors of the biosynthetic pathway, or polyamine analogues that specifically bind DNA. More recently, it has become clear that the natural polyamines are involved in numerous known and unknown cellular processes, and disruption of polyamine functions at their effector sites can potentially produce beneficial therapeutic effects. As new targets for polyamine drug discovery continue to evolve, the rational design of polyamine analogues will result in more structurally diverse agents. In addition, the physical linkage of polyamine-like structures to putative drug molecules can have beneficial effects resulting from increases in DNA affinity and selective cellular uptake. The present chapter will summarize recent advances in the development of alkylpolyamine analogues as antitumour agents, and describe subsequent advances that have resulted from incorporating polyamine character into more diverse drug molecules. Specifically, new polyamine analogues, and the role of polyamine fragments in the design of antiparasitic agents, antitumour metal complexes, histone deacetylase inhibitors and lysine-specific demethylase 1 inhibitors, will be described.

UR - http://www.scopus.com/inward/record.url?scp=77449153146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449153146&partnerID=8YFLogxK

U2 - 10.1042/BSE0460006

DO - 10.1042/BSE0460006

M3 - Article

C2 - 20095971

AN - SCOPUS:77449153146

VL - 46

SP - 77

EP - 94

JO - Essays in Biochemistry

JF - Essays in Biochemistry

SN - 0071-1365

IS - 1

ER -